JP6266659B2 - 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 - Google Patents
癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 Download PDFInfo
- Publication number
- JP6266659B2 JP6266659B2 JP2015560283A JP2015560283A JP6266659B2 JP 6266659 B2 JP6266659 B2 JP 6266659B2 JP 2015560283 A JP2015560283 A JP 2015560283A JP 2015560283 A JP2015560283 A JP 2015560283A JP 6266659 B2 JP6266659 B2 JP 6266659B2
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- compound
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- MANSWCXFKVIKPE-HIJQLYNKSA-N CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(N)=O)c2cc(Cl)ccc2)c(cc2)ccc2Cl)C1=O)(=O)=O Chemical compound CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(N)=O)c2cc(Cl)ccc2)c(cc2)ccc2Cl)C1=O)(=O)=O MANSWCXFKVIKPE-HIJQLYNKSA-N 0.000 description 1
- BEBAQWUEVUWBRD-RTIGCHDFSA-N CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(Nc(cc2)cc(OC)c2C(O)=O)=O)c2cccc(Cl)c2)C(/C=C(\C(\Cl)=C/C)/F)=C)C1=O)(=O)=O Chemical compound CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(Nc(cc2)cc(OC)c2C(O)=O)=O)c2cccc(Cl)c2)C(/C=C(\C(\Cl)=C/C)/F)=C)C1=O)(=O)=O BEBAQWUEVUWBRD-RTIGCHDFSA-N 0.000 description 1
- QGOICCMBEDDFCI-NXQGQTBASA-N CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(Nc(cc2)cc(OC)c2C(O)=O)=O)c2cccc(Cl)c2)c(cc2F)ccc2Cl)C1=O)(=O)=O Chemical compound CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(Nc(cc2)cc(OC)c2C(O)=O)=O)c2cccc(Cl)c2)c(cc2F)ccc2Cl)C1=O)(=O)=O QGOICCMBEDDFCI-NXQGQTBASA-N 0.000 description 1
- IHUMWHKQAVMWCV-HXZUPTHJSA-N CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(O)=O)c2cc(Cl)ccc2)c(cc2F)ccc2Cl)C1=O)(=O)=O Chemical compound CC(C)(C)S(C[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC(O)=O)c2cc(Cl)ccc2)c(cc2F)ccc2Cl)C1=O)(=O)=O IHUMWHKQAVMWCV-HXZUPTHJSA-N 0.000 description 1
- JEGRBRICAOMWLN-LCQQBMRFSA-N CC(C)(C)SC[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC=C)c2cc(Cl)ccc2)c(cc2)ccc2Cl)C1=O Chemical compound CC(C)(C)SC[C@H](C1CC1)N([C@@H]([C@H](C[C@]1(C)CC=C)c2cc(Cl)ccc2)c(cc2)ccc2Cl)C1=O JEGRBRICAOMWLN-LCQQBMRFSA-N 0.000 description 1
- UPKBNWFSKZKMBB-UHFFFAOYSA-N CC(CC(C(c(cc1F)ccc1Cl)=O)c1cc(Cl)ccc1)C(OC)=O Chemical compound CC(CC(C(c(cc1F)ccc1Cl)=O)c1cc(Cl)ccc1)C(OC)=O UPKBNWFSKZKMBB-UHFFFAOYSA-N 0.000 description 1
- ZVXWVVRTWLVZKV-UHFFFAOYSA-N COC(c(cc1F)ccc1Cl)=O Chemical compound COC(c(cc1F)ccc1Cl)=O ZVXWVVRTWLVZKV-UHFFFAOYSA-N 0.000 description 1
- QNQSZYRUBCVBEK-JECHBYEQSA-N C[C@@H](C[C@@H]([C@H](c(cc1)ccc1Cl)O1)c2cc(Cl)ccc2)C1=O Chemical compound C[C@@H](C[C@@H]([C@H](c(cc1)ccc1Cl)O1)c2cc(Cl)ccc2)C1=O QNQSZYRUBCVBEK-JECHBYEQSA-N 0.000 description 1
- QBWGADZCVCWHEF-LQYCBEJQSA-N C[C@@](C[C@H](c1cccc(Cl)c1)O)(CC=C)C(N[C@H](CO)C(C1)[C@@H]1c(c(C)c1)cc(Cl)c1F)=O Chemical compound C[C@@](C[C@H](c1cccc(Cl)c1)O)(CC=C)C(N[C@H](CO)C(C1)[C@@H]1c(c(C)c1)cc(Cl)c1F)=O QBWGADZCVCWHEF-LQYCBEJQSA-N 0.000 description 1
- QNQSZYRUBCVBEK-LQAWEQHXSA-N C[C@H](C[C@@H]([C@H](c(cc1)ccc1Cl)O1)c2cccc(Cl)c2)C1=O Chemical compound C[C@H](C[C@@H]([C@H](c(cc1)ccc1Cl)O1)c2cccc(Cl)c2)C1=O QNQSZYRUBCVBEK-LQAWEQHXSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D211/74—Oxygen atoms
- C07D211/76—Oxygen atoms attached in position 2 or 6
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361770901P | 2013-02-28 | 2013-02-28 | |
| US61/770,901 | 2013-02-28 | ||
| PCT/US2014/018759 WO2014134201A1 (en) | 2013-02-28 | 2014-02-26 | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016510028A JP2016510028A (ja) | 2016-04-04 |
| JP2016510028A5 JP2016510028A5 (enExample) | 2017-02-23 |
| JP6266659B2 true JP6266659B2 (ja) | 2018-01-24 |
Family
ID=50272765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015560283A Active JP6266659B2 (ja) | 2013-02-28 | 2014-02-26 | 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8952036B2 (enExample) |
| EP (1) | EP2961735B1 (enExample) |
| JP (1) | JP6266659B2 (enExample) |
| CN (1) | CN105121407B (enExample) |
| AR (1) | AR094970A1 (enExample) |
| AU (1) | AU2014223547B2 (enExample) |
| CA (1) | CA2902856C (enExample) |
| MX (1) | MX368703B (enExample) |
| TW (1) | TW201505630A (enExample) |
| UY (1) | UY35353A (enExample) |
| WO (1) | WO2014134201A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889632B2 (en) | 2007-01-31 | 2014-11-18 | Dana-Farber Cancer Institute, Inc. | Stabilized p53 peptides and uses thereof |
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
| BR112014009418A2 (pt) | 2011-10-18 | 2017-04-18 | Aileron Therapeutics Inc | macrociclos peptidomiméticos |
| CN112500466B (zh) | 2012-02-15 | 2022-05-03 | 艾瑞朗医疗公司 | 拟肽大环化合物 |
| WO2013123267A1 (en) | 2012-02-15 | 2013-08-22 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| CA2906538C (en) | 2013-03-14 | 2021-02-02 | Ana Gonzalez Buenrostro | Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer |
| JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| TN2016000176A1 (en) | 2013-11-11 | 2017-10-06 | Amgen Inc | Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers. |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| AU2015320549A1 (en) | 2014-09-24 | 2017-04-13 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| CA2974367A1 (en) | 2015-01-20 | 2016-07-28 | Arvinas, Inc. | Compounds and methods for the targeted degradation of the androgen receptor |
| US12312316B2 (en) | 2015-01-20 | 2025-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| SG11201707750YA (en) | 2015-03-20 | 2017-10-30 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
| US20180147202A1 (en) | 2015-06-05 | 2018-05-31 | Arvinas, Inc. | TANK-BINDING KINASE-1 PROTACs AND ASSOCIATED METHODS OF USE |
| EP3337476A4 (en) | 2015-08-19 | 2019-09-04 | Arvinas, Inc. | Compounds and methods for the targeted degradation of bromodomain-containing proteins |
| US9962380B2 (en) * | 2015-09-23 | 2018-05-08 | Wisconsin Alumni Research Foundation | Methods for treating cognitive deficits associated with fragile X syndrome |
| JP7037500B2 (ja) * | 2016-04-06 | 2022-03-16 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | Ｍｄｍ２タンパク質分解剤 |
| UA123168C2 (uk) * | 2016-04-12 | 2021-02-24 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Деструктори білка вет |
| AU2017367872B2 (en) | 2016-11-01 | 2022-03-31 | Arvinas, Inc. | Tau-protein targeting protacs and associated methods of use |
| HRP20231537T1 (hr) | 2016-12-01 | 2024-03-15 | Arvinas Operations, Inc. | Derivati tetrahidronaftalena i tetrahidroizokinolina kao degradatori estrogenskih receptora |
| US11173211B2 (en) | 2016-12-23 | 2021-11-16 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides |
| AU2017382436C1 (en) | 2016-12-23 | 2021-05-27 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of Rapidly Accelerated Fibrosarcoma polypeptides |
| US10806737B2 (en) | 2016-12-23 | 2020-10-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of fetal liver kinase polypeptides |
| US10994015B2 (en) | 2016-12-23 | 2021-05-04 | Arvinas Operations, Inc. | EGFR proteolysis targeting chimeric molecules and associated methods of use |
| US11191741B2 (en) | 2016-12-24 | 2021-12-07 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide |
| BR112019015312A2 (pt) | 2017-01-26 | 2020-03-10 | Arvinas Operations, Inc. | Moduladores da proteólise pelo receptor de estrogênio e métodos de uso associados |
| WO2019099926A1 (en) | 2017-11-17 | 2019-05-23 | Arvinas, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides |
| JP7720698B2 (ja) | 2018-04-04 | 2025-08-08 | アルビナス・オペレーションズ・インコーポレイテッド | タンパク質分解の調節因子および関連する使用方法 |
| IL319432A (en) * | 2018-04-30 | 2025-05-01 | Kartos Therapeutics Inc | Methods of treating cancer |
| JP2021525795A (ja) * | 2018-05-25 | 2021-09-27 | カルトス セラピューティクス，インコーポレイテッド | 骨髄増殖性腫瘍を治療する方法 |
| CN112912376A (zh) | 2018-08-20 | 2021-06-04 | 阿尔维纳斯运营股份有限公司 | 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物 |
| CN110963958B (zh) * | 2018-09-30 | 2025-10-10 | 上海长森药业有限公司 | 一种mdm2抑制剂，及其制备方法、药物组合物和应用 |
| IL290789B2 (en) | 2019-08-26 | 2025-09-01 | Arvinas Operations Inc | Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents |
| JP2023539663A (ja) | 2020-08-28 | 2023-09-15 | アルビナス・オペレーションズ・インコーポレイテッド | 急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法 |
| JP2023541434A (ja) | 2020-09-14 | 2023-10-02 | アルビナス・オペレーションズ・インコーポレイテッド | エストロゲン受容体の標的化分解のための化合物の結晶性形態 |
| US11957759B1 (en) | 2022-09-07 | 2024-04-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use |
| TW202444727A (zh) | 2023-01-26 | 2024-11-16 | 美商艾維納斯手術有限公司 | 基於cereblon之kras降解protac及其相關用途 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH436295A (de) | 1961-11-13 | 1967-05-31 | Mcneilab Inc | Verfahren zur Herstellung neuer 3-Morpholinone |
| DE3246148A1 (de) | 1982-12-14 | 1984-06-14 | Troponwerke GmbH & Co KG, 5000 Köln | Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| WO1995023135A1 (en) | 1991-03-07 | 1995-08-31 | Fisons Corporation | Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity |
| US5334720A (en) | 1991-03-07 | 1994-08-02 | Fisons Corporation | Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties |
| EP1186603A3 (en) | 1994-08-19 | 2003-07-09 | Abbott Laboratories | Processes for preparing endothelin antagonists |
| NZ330818A (en) | 1996-02-13 | 2000-05-26 | Abbott Lab | Benzo-1, 3-dioxolyl- and benzofuranyl substituted pyrrolidine derivatives as endothelin antagonists |
| US6159990A (en) | 1997-06-18 | 2000-12-12 | Synaptic Pharmaceutical Corporation | Oxazolidinones as α1A receptor antagonists |
| PL342500A1 (en) | 1997-08-04 | 2001-06-04 | Abbott Lab | Derivatives of pyrolydin-3-carboxylic acid and their application as endothelin antagonists |
| AU1910299A (en) | 1997-12-18 | 1999-07-05 | Eli Lilly And Company | Peptidomimetic template-based combinatorial libraries |
| US6770658B2 (en) | 1998-09-09 | 2004-08-03 | Inflazyme Pharmaceuticals Ltd. | Substituted γ-phenyl-Δ-lactams and uses related thereto |
| WO2002017912A1 (en) | 2000-08-31 | 2002-03-07 | Abbott Laboratories | Endothelin antagonists |
| CA2436774A1 (en) | 2001-01-30 | 2002-08-08 | R. Michael Lawrence | Sulfonamide lactam inhibitors of factor xa |
| WO2002089738A2 (en) | 2001-05-08 | 2002-11-14 | Yale University | Proteomimetic compounds and methods |
| EP1395560A1 (en) | 2001-05-23 | 2004-03-10 | Ucb, S.A. | 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders |
| RU2305095C2 (ru) | 2001-12-18 | 2007-08-27 | Ф.Хоффманн-Ля Рош Аг | Цис-2,4,5-трифенилимидазолины и фармацевтическая композиция на их основе |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| KR20080027969A (ko) | 2004-05-18 | 2008-03-28 | 에프. 호프만-라 로슈 아게 | 신규 ｃｉｓ-이미다졸린 |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| CA2599476A1 (en) | 2005-03-16 | 2006-09-21 | F. Hoffmann-La Roche Ag | Cis-2,4,5-triaryl-imidazolines and their use as anti-cancer medicaments |
| JP5180816B2 (ja) | 2005-04-04 | 2013-04-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 神経変性疾患および認知症のためのジヒドロピリジン化合物 |
| WO2007063013A1 (en) | 2005-12-01 | 2007-06-07 | F. Hoffmann-La Roche Ag | 2,4,5-triphenyl imidazoline derivatives as inhibitors of the interaction between p53 and mdm2 proteins for use as anticancer agents |
| US20070213341A1 (en) | 2006-03-13 | 2007-09-13 | Li Chen | Spiroindolinone derivatives |
| CN101595107A (zh) | 2006-06-30 | 2009-12-02 | 先灵公司 | 能提高p53活性的有取代哌啶及其用途 |
| US20100092427A1 (en) | 2006-07-19 | 2010-04-15 | The University Of Georgia Research Foundation | Pyridinone Diketo Acids: Inhibitors of HIV Replication in Combination Therapy |
| US20080045560A1 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Pyrrolidine and related derivatives useful as PR modulators |
| WO2008021338A2 (en) | 2006-08-15 | 2008-02-21 | Wyeth | Tricyclic oxazolidone derivatives useful as pr modulators |
| TW200831080A (en) | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| GB0722769D0 (en) | 2007-11-21 | 2008-01-02 | Biolipox Ab | New compounds |
| US7625895B2 (en) | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| WO2008130614A2 (en) | 2007-04-20 | 2008-10-30 | University Of Pittsburg-Of The Commonwealth System Of Higher Education | Selective and dual-action p53/mdm2/mdm4 antagonists |
| US7834179B2 (en) | 2007-05-23 | 2010-11-16 | Hoffmann-La Roche Inc. | Spiroindolinone derivatives |
| WO2009004430A1 (en) | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
| ES2395210T3 (es) | 2007-10-09 | 2013-02-11 | F. Hoffmann-La Roche Ag | Cis-Imidazolinas quirales |
| US7776875B2 (en) | 2007-12-19 | 2010-08-17 | Hoffman-La Roche Inc. | Spiroindolinone derivatives |
| US20100256191A1 (en) | 2007-12-26 | 2010-10-07 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
| WO2009114950A1 (en) | 2008-03-21 | 2009-09-24 | Chlorion Pharma, Inc. | Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
| RU2506257C2 (ru) | 2008-09-18 | 2014-02-10 | Ф.Хоффманн-Ля Рош Аг | Замещенные пирролидин-2-карбоксамиды |
| US8076482B2 (en) | 2009-04-23 | 2011-12-13 | Hoffmann-La Roche Inc. | 3,3′-spiroindolinone derivatives |
| CN102574785A (zh) | 2009-08-26 | 2012-07-11 | 诺瓦提斯公司 | 四取代的杂芳基化合物和它们作为mdm2和/或mdm4调节剂的用途 |
| US8088815B2 (en) * | 2009-12-02 | 2012-01-03 | Hoffman-La Roche Inc. | Spiroindolinone pyrrolidines |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| JO2998B1 (ar) * | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| US20120010235A1 (en) * | 2010-07-12 | 2012-01-12 | Xin-Jie Chu | N-substituted pyrrolidines |
| US20120046306A1 (en) * | 2010-08-18 | 2012-02-23 | David Joseph Bartkovitz | Substituted Heteroaryl Spiropyrrolidine MDM2 Antagonists |
| CN102153557B (zh) | 2011-01-21 | 2013-03-20 | 中国科学院上海有机化学研究所 | 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途 |
| JP6093770B2 (ja) | 2011-09-27 | 2017-03-08 | アムジエン・インコーポレーテツド | 癌の治療のためのｍｄｍ２阻害剤としての複素環化合物 |
-
2014
- 2014-02-26 MX MX2015011245A patent/MX368703B/es active IP Right Grant
- 2014-02-26 CA CA2902856A patent/CA2902856C/en active Active
- 2014-02-26 JP JP2015560283A patent/JP6266659B2/ja active Active
- 2014-02-26 WO PCT/US2014/018759 patent/WO2014134201A1/en not_active Ceased
- 2014-02-26 CN CN201480011184.XA patent/CN105121407B/zh active Active
- 2014-02-26 AU AU2014223547A patent/AU2014223547B2/en active Active
- 2014-02-26 EP EP14709849.5A patent/EP2961735B1/en active Active
- 2014-02-27 TW TW103106905A patent/TW201505630A/zh unknown
- 2014-02-27 UY UY0001035353A patent/UY35353A/es not_active Application Discontinuation
- 2014-02-27 US US14/192,553 patent/US8952036B2/en active Active
- 2014-02-28 AR ARP140100685A patent/AR094970A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015011245A (es) | 2016-05-31 |
| JP2016510028A (ja) | 2016-04-04 |
| TW201505630A (zh) | 2015-02-16 |
| US8952036B2 (en) | 2015-02-10 |
| WO2014134201A1 (en) | 2014-09-04 |
| AU2014223547B2 (en) | 2017-11-16 |
| US20140243372A1 (en) | 2014-08-28 |
| CN105121407A (zh) | 2015-12-02 |
| CA2902856C (en) | 2021-02-16 |
| EP2961735B1 (en) | 2017-09-27 |
| EP2961735A1 (en) | 2016-01-06 |
| MX368703B (es) | 2019-10-11 |
| CN105121407B (zh) | 2017-07-18 |
| UY35353A (es) | 2014-09-30 |
| AR094970A1 (es) | 2015-09-09 |
| AU2014223547A1 (en) | 2015-09-03 |
| CA2902856A1 (en) | 2014-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6266659B2 (ja) | 癌の治療のための安息香酸誘導体ｍｄｍ２阻害剤 | |
| EP2576510B1 (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| JP6377123B2 (ja) | 癌の治療のためのｍｄｍ２阻害剤としてのヘテロアリール酸モルホリノン化合物 | |
| EP2376478B1 (en) | Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease | |
| JP2023527891A (ja) | がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体 | |
| EP3790867B1 (en) | Kdm1a inhibitors for the treatment of disease | |
| JP6417338B2 (ja) | 癌の治療のためのｍｄｍ２阻害剤としてのシス−モルホリノン及び他の化合物 | |
| JP2019530649A (ja) | 統合ストレス経路のモジュレーター | |
| EP2334683B1 (en) | Saturated bicyclic heterocyclic derivatives as smo antagonists | |
| JPWO2005103012A1 (ja) | ヒドラジノ複素環ニトリル化合物およびその用途 | |
| HK1215707B (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer | |
| HK1182711B (en) | Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170119 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170119 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20171128 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20171130 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171220 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6266659 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |